Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | B2M LOH |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
B2M LOH | melanoma | predicted - resistant | Ipilimumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, B2M loss of heterozygosity (LOH) was significantly enriched in pre-treatment biopsies of melanoma patients who did not respond to Yervoy (ipilimumab) compared to those who responded (20/69, 28.9% vs 4/36, 11.1%, p=0.01), and was associated with poorer overall survival (p=0.01) (PMID: 29070816). | 29070816 | |
B2M LOH | melanoma | predicted - resistant | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, the presence of B2M loss of heterozygosity (LOH) in the pre-treatment biopsies was significantly associated with worse overall survival (p=0.006) in melanoma patients treated with Keytruda (pembrolizumab) (PMID: 29070816). | 29070816 |